ストックスクリーナーアプリを入手
0.5229
3.26%
0.0165
プレマーケット:
.52
-0.0029
-0.55%
Context Therapeutics Inc (CNTX) 最新ニュース
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Context Therapeutics Inc. (CNTX) Stock Price, News, Quote & History - Yahoo Finance
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
CNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingView
Weekly Recap: CNTX Nasdaq notice and Q2 2026 $0.09 loss forecast - TradingView
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Context Therapeutics (CNTX): Octagon group reports 3.3% beneficial stake in Schedule 13G/A - Stock Titan
Context Therapeutics (CNTX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – FWB:6K9 - TradingView
CNTX|Context Therapeutics Inc|Price:0.603|Chg%:+0.003 - TradingKey
BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX) - Stock Titan
Octagon Capital Advisors LP Takes $13.76 Million Position in Context Therapeutics Inc. $CNTX - MarketBeat
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Balance Sheet - TradingKey
Context Therapeutics Inc (CNTX) Income Statement - TradingKey
Context Therapeutics Inc (CNTX) Cash Flow - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Earnings Date & Reports & Earnings News - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – SWB:6K9 - TradingView
Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX - TradingView
Context Therapeutics Inc. (CNTX) Slips 2.7% as Shares Approach Key SupportGamma Squeeze - po-news-eg.net
Context Therapeutics (NASDAQ:CNTX) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
CNTX Q1 2026 Earnings: Beat on EPS as Clinical Pipeline AdvancesEarnings Manipulation Risk - dars.gov.et
SRNE stock holds on Sorrento Therapeutics identity and filing context - ad-hoc-news.de
Context Therapeutics Inc. (CNTX) Q1 2026 Earnings: Narrowing Loss Beats Street Estimates, Stock Holds Steady - dars.gov.et
Enterprise value to revenue forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Grants 146,000-Share Option to New Employee - MyChesCo
Context Therapeutics Q1 2026 Earnings: EPS Beat by 24.81% Offset by Stock Decline Amid Pre-Revenue Stage - dars.gov.et
Context Therapeutics (CNTX) Proxy filing Summary - Quartr
Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary - Quartr
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Context Therapeutics hire receives 146,000-share stock option at $0.70 - Stock Titan
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst - TipRanks
Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes - 富途牛牛
Context Therapeutics (CNTX) Surges Nearly 10% as Momentum BuildsSafe Entry Stocks - dars.gov.et
Context Therapeutics Joins Russell 2000, Russell 3000 Indexes - Moomoo
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):